AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Go back to AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis| AbbVie (NYSE: ABBV) | Delayed: 230.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $230.01 | 52 Week Low | $50.71 | |||
| Day High | $230.01 | P/E | 49.89 | |||
| Day Low | $230.01 | EPS | $4.61 | |||
| Volume | 2,927 | |||||
